Találati lista | Tudóstér

001-es BibID:	BIBFORM116048
035-os BibID:	(WoS)001099534000001 (Scopus)85176459124
Első szerző:	Karpouzas, George A.
Cím:	Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors : a post hoc analysis of ORAL Surveillance / George A. Karpouzas, Zoltán Szekanecz, Eva Baecklund, Ted R. Mikuls, Deepak L. Bhatt, Cunshan Wang, Gosford A. Sawyerr, Yan Chen, Sujatha Menon, Carol A. Connell, Steven R. Ytterberg, Mahta Mortezavi
Dátum:	2023
ISSN:	1759-720X 1759-7218
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Therapeutic Advances in Musculoskeletal Disease. - 15 (2023), p. 1-14. -
További szerzők:	Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Baecklund, Eva Mikuls, Ted R. Bhatt, Deepak L. Wang, Cunshan Sawyerr, Gosford A. Chen, Yan Menon, Sujatha Connell, Carol A. Ytterberg, Steven R. Mortezavi, Mahta
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM117872
035-os BibID:	(WoS)001142644000003 (Scopus)85182237892
Első szerző:	Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:	Efficacy and safety of JAK inhibitors in rheumatoid arthritis : update for the practising clinician / Zoltán Szekanecz, Maya H. Buch, Christina Charles-Schoeman, James Galloway, George A. Karpouzas, Lars Erik Kristensen, Steven R. Ytterberg, Attila Hamar, Roy Fleischmann
Dátum:	2024
ISSN:	1759-4790 1759-4804
Megjegyzések:	Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the issuance of guidance by regulatory agencies advising caution in their use in certain patients. The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events (MACEs), venous thromboembolism, malignancies or infections (other than herpes zoster) with a JAK inhibitor versus a biologic DMARD. In the ORAL Surveillance trial, which enrolled patients >50 years of age with ?1 cardiovascular risk factor, tofacitinib was statistically inferior to TNF inhibitors for the occurrence of MACEs and malignancy. Further post hoc analysis of the data revealed that an age of ?65 years, a high baseline cardiovascular risk, a history of smoking, sustained inflammation, disease activity and suboptimal treatment of cardiovascular comorbidities all increase the risk of these outcomes. The guidance issued by regulatory agencies should be carefully considered to ensure appropriate and safe treatment of patients with RA without undertreatment of patients who might benefit from JAK inhibitor, as well as biologic, treatment. As always, the risks associated with the use of these agents, treatment goals, costs and patient preferences should be discussed with the patient.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Nature Reviews Rheumatology. - 20 : 2 (2024), p. 101-115. -
További szerzők:	Buch, Maya H. Charles-Schoeman, Christina Galloway, James Karpouzas, George A. Kristensen, Lars Erik Ytterberg, Steven R. Hamar Attila Béla (1990-) (általános orvos) Fleischmann, Roy
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: